SG11201408419QA - Method for preparing substituted triazolopyridines - Google Patents

Method for preparing substituted triazolopyridines

Info

Publication number
SG11201408419QA
SG11201408419QA SG11201408419QA SG11201408419QA SG11201408419QA SG 11201408419Q A SG11201408419Q A SG 11201408419QA SG 11201408419Q A SG11201408419Q A SG 11201408419QA SG 11201408419Q A SG11201408419Q A SG 11201408419QA SG 11201408419Q A SG11201408419Q A SG 11201408419QA
Authority
SG
Singapore
Prior art keywords
international
str
preparing substituted
monheim
english
Prior art date
Application number
SG11201408419QA
Other languages
English (en)
Inventor
Volker Schulze
Franz-Josef Mais
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SG11201408419QA publication Critical patent/SG11201408419QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201408419QA 2012-07-10 2013-07-03 Method for preparing substituted triazolopyridines SG11201408419QA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12175640 2012-07-10
EP12185590 2012-09-24
EP13170585 2013-06-05
PCT/EP2013/064017 WO2014009219A1 (en) 2012-07-10 2013-07-03 Method for preparing substituted triazolopyridines

Publications (1)

Publication Number Publication Date
SG11201408419QA true SG11201408419QA (en) 2015-01-29

Family

ID=48793197

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408419QA SG11201408419QA (en) 2012-07-10 2013-07-03 Method for preparing substituted triazolopyridines

Country Status (24)

Country Link
US (1) US9388177B2 (me)
EP (1) EP2872506A1 (me)
JP (1) JP6238979B2 (me)
KR (1) KR20150040845A (me)
CN (1) CN104603136B (me)
AP (1) AP3778A (me)
AU (1) AU2013289381A1 (me)
BR (1) BR112015000308A2 (me)
CA (1) CA2878481A1 (me)
CL (1) CL2015000038A1 (me)
CO (1) CO7160002A2 (me)
CR (1) CR20150006A (me)
DO (1) DOP2015000007A (me)
EA (1) EA027544B1 (me)
HK (1) HK1206731A1 (me)
IL (1) IL236265A (me)
IN (1) IN2015DN00085A (me)
MX (1) MX2015000348A (me)
NZ (1) NZ703020A (me)
PE (1) PE20150354A1 (me)
PH (1) PH12015500061A1 (me)
SG (1) SG11201408419QA (me)
TN (1) TN2015000008A1 (me)
WO (1) WO2014009219A1 (me)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160264568A1 (en) * 2013-06-07 2016-09-15 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines having activity as mps-1 inhibitors
PE20160156A1 (es) * 2013-06-11 2016-04-20 Bayer Pharma AG Derivados de prodroga de triazolpiridinas sustituidas
KR20160018534A (ko) 2013-06-11 2016-02-17 바이엘 파마 악티엔게젤샤프트 Mps-1 키나제 억제제 및 유사분열 억제제를 포함하는 암의 치료를 위한 조합물
ES2966392T3 (es) 2015-04-17 2024-04-22 Crossfire Oncology Holding B V Biomarcadores pronósticos para quimioterapia inhibidora de TTK
TW201800408A (zh) 2016-06-15 2018-01-01 拜耳製藥公司 Mps-1抑制劑

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050009812A1 (en) * 2001-10-05 2005-01-13 Takuya Seko Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists
MXPA06013250A (es) * 2004-05-14 2007-02-28 Abbott Lab Inhibidores de quinasa como agentes terapeuticos.
UA89503C2 (uk) * 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
JP2008515874A (ja) * 2004-10-07 2008-05-15 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌薬
US20060194823A1 (en) * 2004-12-22 2006-08-31 Georg Kettschau Sulfonamido-macrocycles as Tie2 inhibitors and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof
MX2008015747A (es) * 2006-06-06 2008-12-19 Schering Corp Imidazopirazinas como inhibidores de la proteina quinasa.
EP1870416A1 (en) * 2006-06-21 2007-12-26 Bayer Schering Pharma Aktiengesellschaft Sulphonamido-macrocycles as tie2 inhibitors
BRPI0716239A2 (pt) 2006-08-30 2013-08-13 Cellzome Ltd derivados de triazol como inibidores de cinase
JO3598B1 (ar) * 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
BRPI0813831A2 (pt) 2007-07-18 2015-01-06 Novartis Ag Compostos de heteroarila bicíclica e seu uso como inibidores de quinase
KR20100057650A (ko) 2007-08-23 2010-05-31 아스트라제네카 아베 증식성 질환의 치료를 위한 ttk/mps1의 억제제로서 2-아닐리노푸린-8-온
EP2181112A1 (en) 2007-08-31 2010-05-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB0724342D0 (en) * 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
WO2009137322A2 (en) * 2008-05-05 2009-11-12 The Trustees Of The University Of Pennsylvania Processes for the preparation of biphenyl compounds
EP2303890A4 (en) * 2008-06-19 2012-04-11 Progenics Pharm Inc INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE
PE20120110A1 (es) 2009-02-13 2012-02-20 Fovea Pharmaceuticals [1,2,4]triazolo[1,5-a]piridinas como inhibidores de cinasa
EP2424537B1 (en) 2009-04-29 2015-07-08 Bayer Intellectual Property GmbH Substituted imidazoquinoxalines
CA2763900A1 (en) * 2009-06-05 2010-12-09 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
WO2010141360A1 (en) * 2009-06-05 2010-12-09 Merck Sharp & Dohme Corp. Biaryl benzotriazole derivatives
JP5728683B2 (ja) 2009-09-04 2015-06-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
WO2012044567A2 (en) * 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Imidazole derivatives
CA2833657A1 (en) * 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Triazolopyridines
WO2012160029A1 (en) * 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk

Also Published As

Publication number Publication date
CA2878481A1 (en) 2014-01-16
EA201590116A1 (ru) 2015-07-30
NZ703020A (en) 2017-08-25
WO2014009219A1 (en) 2014-01-16
IL236265A (en) 2017-07-31
TN2015000008A1 (en) 2016-06-29
CO7160002A2 (es) 2015-01-15
IL236265A0 (en) 2015-02-26
IN2015DN00085A (me) 2015-05-29
DOP2015000007A (es) 2015-02-15
CN104603136B (zh) 2017-06-27
BR112015000308A2 (pt) 2017-06-27
PH12015500061A1 (en) 2015-03-02
JP6238979B2 (ja) 2017-11-29
PE20150354A1 (es) 2015-03-21
MX2015000348A (es) 2015-04-14
US20150148542A1 (en) 2015-05-28
HK1206731A1 (en) 2016-01-15
EA027544B1 (ru) 2017-08-31
KR20150040845A (ko) 2015-04-15
EP2872506A1 (en) 2015-05-20
US9388177B2 (en) 2016-07-12
AU2013289381A1 (en) 2015-01-22
AP2014008177A0 (en) 2014-12-31
AP3778A (en) 2016-08-31
CN104603136A (zh) 2015-05-06
JP2015523372A (ja) 2015-08-13
CR20150006A (es) 2015-02-16
CL2015000038A1 (es) 2015-03-13

Similar Documents

Publication Publication Date Title
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201408261UA (en) Syringe
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201408094YA (en) Neprilysin inhibitors
SG11201408641UA (en) Phenoxyethyl piperidine compounds
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201908640TA (en) Pyrrolidinones and a process to prepare them
SG11201407200TA (en) Liquid formulation
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201408237YA (en) Compound as wnt signaling inhibitor, composition, and use thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201407037UA (en) Catechol o-methyltransferase activity inhibiting compounds
SG11201407596TA (en) Conjugation reagents
SG11201402986RA (en) Kinase inhibitors
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201808686VA (en) Synthesis of indazoles
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea
SG11201406787TA (en) Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies
SG11201407345QA (en) Pyrazole compounds as sglt1 inhibitors
SG11201811671XA (en) Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
SG11201408419QA (en) Method for preparing substituted triazolopyridines
SG11201408502XA (en) Method of purifying an antibody
SG11201406745VA (en) Methods of therapeutic monitoring of phenylacetic acid prodrugs